Key terms
About ELEV
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ELEV news
Apr 09
6:17am ET
Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology
Apr 08
4:35pm ET
Elevation Oncology presents preclinical proof-of concept data for HER3-ADC
Apr 05
4:34pm ET
Lori Hu Resigns, Darcy Mootz Joins Elevation Oncology Board
Mar 20
8:31am ET
Four new option listings on March 20th
Mar 11
1:00am ET
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Mar 08
1:02am ET
A New Cause for Concern: Elevation Oncology, Inc. Adds a New Debt & Financing Risk
Mar 07
2:25pm ET
Elevation Oncology (ELEV) Receives a Buy from TD Cowen
Mar 07
8:14am ET
Elevation Oncology price target raised to $8 from $5 at Wedbush
Mar 07
6:26am ET
Elevation Oncology: A Strong Buy on Robust Financials and Promising Clinical Pipeline
Mar 07
12:30am ET
Analysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)
Mar 06
7:32am ET
Elevation Oncology reports Q4 EPS (19c), consensus (24c)
Mar 01
9:46am ET
GoodRx upgraded, Fisker downgraded: Wall Street’s top analyst calls
Mar 01
4:48am ET
Elevation Oncology initiated with an Outperform at JMP Securities
Mar 01
12:25am ET
Optimistic Buy Rating for Elevation Oncology on EO-3021’s Promising Clinical Advancements and Differentiation
Feb 22
7:38am ET
Elevation Oncology doses first patient in Japan in Phase 1 trial of EO-3021
Feb 20
6:14am ET
Elevation Oncology price target raised to $6 from $1.50 at H.C. Wainwright
Jan 23
3:08am ET
Elevation Oncology Appoints Darcy Mootz as New Director
Apr 15
8:30am ET
INVESTOR ALERT: Kaskela Law LLC Announces Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
Mar 14
4:15am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
ELEV Financials
Key terms
Ad Feedback
ELEV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ELEV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
